These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37894345)

  • 1. Deletions of
    Vrugt B; Kirschner MB; Meerang M; Oehl K; Wagner U; Soltermann A; Moch H; Opitz I; Wild PJ
    Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894345
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry.
    Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Iwasaki A; Okamoto T; Oda Y; Honda H; Nabeshima K
    Lung Cancer; 2017 Feb; 104():98-105. PubMed ID: 28213009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of MTAP and BAP1 staining loss and P16/CDKN2A deletion in pleural cytology specimens and its role in the diagnosis of mesothelioma.
    Şeker NS; Tekin E; Ak G; Metintaş M; Metintaş S; Dündar E
    Diagn Cytopathol; 2024 Apr; 52(4):211-216. PubMed ID: 38243885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges and limitation of MTAP immunohistochemistry in diagnosing desmoplastic mesothelioma/sarcomatoid pleural mesothelioma with desmoplastic features.
    Sa-Ngiamwibool P; Hamasaki M; Kinoshita Y; Matsumoto S; Sato A; Tsujimura T; Kasai T; Hiroshima K; Kushitani K; Takeshima Y; Kawahara K; Iwasaki A; Nabeshima K
    Ann Diagn Pathol; 2022 Oct; 60():152004. PubMed ID: 35797798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Combination of MTAP and p16 Immunohistochemistry Can Substitute for CDKN2A Fluorescence In Situ Hybridization in Diagnosis and Prognosis of Pleural Mesotheliomas.
    Brcic L; Le Stang N; Gallob F; Pissaloux D; Sequeiros R; Paindavoine S; Pairon JC; Karanian M; Dacic S; Girard N; Churg A; Tirode F; Galateau-Salle F
    Arch Pathol Lab Med; 2023 Mar; 147(3):313-322. PubMed ID: 35738002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Immunohistochemistry, Next-generation Sequencing and Fluorescence In Situ Hybridization for Detection of MTAP Loss in Pleural Mesothelioma.
    Febres-Aldana CA; Chang JC; Jungbluth AA; Adusumilli PS; Bodd FM; Frosina D; Geronimo JA; Hernandez E; Irawan H; Offin MD; Rekhtman N; Travis WD; Vanderbilt C; Zauderer MG; Zhang Y; Ladanyi M; Yang SR; Sauter JL
    Mod Pathol; 2024 Mar; 37(3):100420. PubMed ID: 38185249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concordant loss of MTAP and p16/CDKN2A expression in gastroesophageal carcinogenesis: evidence of homozygous deletion in esophageal noninvasive precursor lesions and therapeutic implications.
    Powell EL; Leoni LM; Canto MI; Forastiere AA; Iocobuzio-Donahue CA; Wang JS; Maitra A; Montgomery E
    Am J Surg Pathol; 2005 Nov; 29(11):1497-504. PubMed ID: 16224217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival.
    Krasinskas AM; Bartlett DL; Cieply K; Dacic S
    Mod Pathol; 2010 Apr; 23(4):531-8. PubMed ID: 20081810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concordance between CDKN2A homozygous deletion and MTAP immunohistochemical loss in fluoroedenite-induced pleural mesothelioma: An immunohistochemical and molecular study on a single-institution series.
    Broggi G; Massimino M; Failla M; Filetti V; Rapisarda V; Ledda C; Lombardo C; Loreto C; Vigneri P; Caltabiano R
    Pathol Res Pract; 2024 Jul; 259():155350. PubMed ID: 38781764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of methylthioadenosine phosphorylase (MTAP) protein expression with MTAP and CDKN2A copy number in malignant pleural mesothelioma.
    Chapel DB; Dubuc AM; Hornick JL; Sholl LM
    Histopathology; 2021 Jun; 78(7):1032-1042. PubMed ID: 33387364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDKN2A and MTAP Are Useful Biomarkers Detectable by Droplet Digital PCR in Malignant Pleural Mesothelioma: A Potential Alternative Method in Diagnosis Compared to Fluorescence
    Cheng YY; Yuen ML; Rath EM; Johnson B; Zhuang L; Yu TK; Aleksova V; Linton A; Kao S; Clarke CJ; McCaughan BC; Takahashi K; Lee K
    Front Oncol; 2020; 10():579327. PubMed ID: 33304846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing loss of p16 and MTAP expression in detecting CDKN2A homozygous deletion in pleomorphic xanthoastrocytoma.
    Vizcaino MA; Giannini C; Vaubel RA; Nguyen AT; Trejo-Lopez JA; Raghunathan A; Jenkins SM; Jenkins RB; Zepeda Mendoza CJ
    J Neuropathol Exp Neurol; 2024 Dec; 83(12):1003-1009. PubMed ID: 39042515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of MTAP and p16 immunohistochemical deficiency as surrogate marker for CDKN2A/B homozygous deletion in gliomas.
    Maragkou T; Reinhard S; Jungo P; Pasquier B; Neuenschwander M; Schucht P; Vassella E; Hewer E
    Pathology; 2023 Jun; 55(4):466-477. PubMed ID: 37032198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MTAP and p16 IHC as Markers for CDKN2A/B Loss in Meningiomas.
    Ozkizilkaya HI; Vinocha A; Dono A; Ogunbona OB; Toruner GA; Aung PP; Kamiya Matsuoka C; Esquenazi Y; DeMonte F; Ballester LY
    Cancers (Basel); 2024 Sep; 16(19):. PubMed ID: 39409918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Methylthioadenosine phosphorylase and p16 as surrogate diagnostic markers for CDKN2A homozygous deletion in brain tumors].
    Wang SN; Wang W; Zhang XW; Zhang YQ; Xiong YL; Liu L; Teng LH
    Zhonghua Bing Li Xue Za Zhi; 2024 May; 53(5):439-445. PubMed ID: 38678323
    [No Abstract]   [Full Text] [Related]  

  • 16. Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma.
    Brich S; Bozzi F; Perrone F; Tamborini E; Cabras AD; Deraco M; Stacchiotti S; Dagrada GP; Pilotti S
    Mod Pathol; 2020 Feb; 33(2):217-227. PubMed ID: 31570769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
    McGregor SM; McElherne J; Minor A; Keller-Ramey J; Dunning R; Husain AN; Vigneswaran W; Fitzpatrick C; Krausz T
    Hum Pathol; 2017 Feb; 60():86-94. PubMed ID: 27771374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas.
    Illei PB; Rusch VW; Zakowski MF; Ladanyi M
    Clin Cancer Res; 2003 Jun; 9(6):2108-13. PubMed ID: 12796375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma.
    Chapel DB; Schulte JJ; Berg K; Churg A; Dacic S; Fitzpatrick C; Galateau-Salle F; Hiroshima K; Krausz T; Le Stang N; McGregor S; Nabeshima K; Husain AN
    Mod Pathol; 2020 Feb; 33(2):245-254. PubMed ID: 31231127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis.
    Kinoshita Y; Hamasaki M; Yoshimura M; Matsumoto S; Sato A; Tsujimura T; Ueda H; Makihata S; Kato F; Iwasaki A; Nabeshima K
    Lung Cancer; 2018 Nov; 125():198-204. PubMed ID: 30429020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.